Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we unpack acute interstitial nephritis (AIN)—a frequently overlooked cause of acute kidney injury (AKI) driven largely by medications, immune reactions, and systemic diseases. We start with epidemiology clinicians should recognize. AIN accounts for roughly 15–27% of kidney biopsies performed for AKI and about 2.8% of all kidney biopsies overall. Among biopsies done specifically for acute renal failure, AIN represents ~13.5% of cases. Drug-induced AIN dominates the landscape, responsible for 70–90% of biopsy-proven cases, and its incidence appears to be rising—particularly in older adults, where polypharmacy and underutilization of kidney biopsy can obscure the diagnosis. Next we break down the most common causes.• Antibiotics are the leading class, responsible for ~49% of drug-induced AIN, especially penicillins, cephalosporins, rifampin, and fluoroquinolones.• Proton pump inhibitors account for ~14%, with omeprazole the single most common culprit drug.• NSAIDs (~11%) are another major contributor.Other causes include 5-aminosalicylates, diuretics, allopurinol, anticonvulsants, and chemotherapeutic agents. Emerging causes include immune checkpoint inhibitors, reflecting the expanding use of immunotherapy in oncology. We then explore the immunologic pathophysiology. AIN is primarily driven by T-cell–mediated hypersensitivity reactions (Type IV) targeting tubular antigens or drug-related antigens processed by tubular epithelial cells. However, IgE-mediated mast cell activation (Type I hypersensitivity) may also contribute in some cases. The resulting interstitial inflammation and edema can rapidly progress to fibrosis, making early recognition and treatment critical for renal recovery. Histologically, AIN is characterized by interstitial inflammatory infiltrates composed mainly of lymphocytes, macrophages, plasma cells, and sometimes eosinophils, along with tubulitis, interstitial edema, and tubular injury. Glomeruli are typically normal, while interstitial fibrosis and tubular atrophy signal chronicity and worse prognosis. Variants include granulomatous AIN and rare entities like IgM-positive plasma cell tubulointerstitial nephritis. Clinically, the classic triad of fever, rash, and eosinophilia is now uncommon—present in fewer than 10–15% of patients. Instead, most patients present with nonspecific symptoms such as malaise, nausea, or asymptomatic AKI. Non-oliguric AKI is typical, often accompanied by mild proteinuria and tubular dysfunction. Diagnosis relies on clinical suspicion, medication review, and supportive laboratory findings. Urinalysis may show sterile pyuria and white blood cell casts, which are more specific for AIN. Eosinophiluria, historically emphasized, is neither sensitive nor specific. Ultimately, kidney biopsy remains the gold standard when the diagnosis is uncertain. We also review emerging biomarkers that may transform diagnosis. Urinary CXCL9, an interferon-γ–induced chemokine involved in lymphocyte recruitment, has shown excellent diagnostic performance with AUC values up to ~0.94 for AIN detection. Additional candidate biomarkers include urinary TNF-α, IL-9, kidney injury molecule-1 (KIM-1), and soluble C5b-9, reflecting tubular injury and immune activation. Management begins with immediate withdrawal of the offending drug. If kidney function does not improve within 5–7 days, corticosteroid therapy is often initiated, typically prednisone ~40–60 mg daily (~0.8 mg/kg). Evidence suggests that early steroid therapy—within the first 1–2 weeks—improves renal recovery, while prolonged treatment beyond several weeks offers little additional benefit. Finally, we discuss prognosis. About 76% of patients achieve some degree of kidney recovery within six months, with complete recovery in roughly half of steroid-treated cases. However, chronic kidney disease remains common, and long-term studies suggest up to 39% of patients may eventually develop end-sta

In this episode of Hospital Medicine Unplugged, we tackle polypharmacy and deprescribing—how to recognize problematic medication overload, quantify its harms, and apply structured, patient-centered strategies to safely reduce medication burden. We begin with definitions that shape clinical practice. Polypharmacy is most commonly defined as the use of ≥5 medications, though definitions vary. Importantly, not all polypharmacy is harmful. “Appropriate polypharmacy” occurs when medications are evidence-based and optimized, while “problematic polypharmacy” arises when medications lack clear benefit or when harms outweigh benefits. Deprescribing is the systematic process of identifying and discontinuing medications whose risks exceed benefits, aligned with a patient’s goals, function, life expectancy, and preferences. Next we review how common this problem is. Polypharmacy affects 30–40% of community-dwelling older adults, 40–50% of hospitalized older adults, and up to 90% of nursing home residents. Roughly 20–50% of older adults take at least one potentially inappropriate medication (PIM). Risk rises with multimorbidity, female sex, lower socioeconomic status, and each additional chronic disease increases the odds of polypharmacy by nearly 90%. We then quantify the clinical consequences.• Adverse drug events occur in 20–30% of hospitalized older adults, and each additional medication increases adverse reaction risk by ~10%.• Polypharmacy is associated with higher mortality (HR ~1.2–1.7) and increased hospital admissions and readmissions.• It also increases fall risk (OR ~1.6) and contributes to hip fractures, frailty, cognitive impairment, and functional decline. A key driver is the prescribing cascade, where a drug causes side effects that are treated with additional medications. Classic examples include:• NSAIDs → hypertension → antihypertensives• Cholinesterase inhibitors → urinary incontinence → anticholinergics• Calcium channel blockers → edema → diuretics• Antipsychotics → parkinsonism → antiparkinsonian drugs To identify problematic medications, we review major screening tools.• 2023 AGS Beers Criteria highlights medications to avoid or use cautiously in older adults, including guidance on benzodiazepines, antipsychotics in dementia, and aspirin for primary prevention in adults ≥70.• STOPP/START version 3 includes 94 criteria for inappropriate prescriptions and 34 for underprescribing.• Additional tools include the Medication Appropriateness Index, FORTA classification, Anticholinergic Cognitive Burden scale, and Drug Burden Index. We then walk through a practical deprescribing framework. A common 5-step protocol includes: List all medications and indications Assess overall risk of drug-related harm Identify drugs eligible for discontinuation Prioritize those with highest harm and lowest benefit Implement tapering and monitor for withdrawal or recurrence Certain medications require careful tapering to prevent withdrawal syndromes, including benzodiazepines, beta-blockers, antidepressants, corticosteroids, opioids, antiepileptics, clonidine, baclofen, and proton pump inhibitors. We highlight high-yield deprescribing targets.• Proton pump inhibitors: up to 70% lack appropriate indication; associated with C. difficile infection, pneumonia, CKD, and fractures.• Benzodiazepines: linked to falls, delirium, and cognitive impairment, with tapering success rates 27–80%.• Antipsychotics: frequently used for dementia behaviors but carry 1.6–1.7× increased mortality risk.• Anticholinergic medications: high burden strongly linked to cognitive decline and mortality.• Sliding-scale insulin: increases hypoglycemia without improving glycemic control. We also discuss patient and system barriers. Interestingly, 92% of older adults say they would stop at least one medication if their doctor recommended it, though many fear symptom recurrence or believe medications are necessary. Finally, we examine solutions that work. P

In this episode of Hospital Medicine Unplugged, we break down ANCA-associated vasculitis (AAV)—granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA)—focusing on modern epidemiology, complement-driven pathophysiology, ANCA serotypes, and the rapidly evolving treatment landscape. We start with epidemiology clinicians should recognize. The global incidence of AAV is ~17 per million person-years, with a prevalence near 198 per million. In the United States, incidence is roughly 3.3 per 100,000, with a prevalence of ~42 per 100,000. Subtype incidence varies: GPA (~9–15/million), MPA (~6/million), and EGPA (~2/million). The mean age at diagnosis is about 61, and rates have increased over the past decades due to greater recognition and widespread ANCA testing. Next we unpack the pathophysiology that changed therapy. Complement activation—particularly the alternative pathway—plays a central role. C5a drives neutrophil activation and recruitment, creating an inflammatory amplification loop. Low C3 levels correlate with more aggressive disease and worse renal outcomes. This mechanistic insight led to avacopan, an oral C5a receptor antagonist that provides a glucocorticoid-sparing approach to treatment. We then highlight the importance of ANCA serotype classification. Patients are increasingly categorized by PR3-ANCA vs MPO-ANCA, not just clinical phenotype.• PR3-ANCA disease is more often GPA, with ENT involvement, pulmonary nodules, and higher relapse risk.• MPO-ANCA disease more often presents as MPA, with renal-limited disease, interstitial lung disease, and higher mortality. We also review EGPA as a distinct entity. Only ~40% of patients are ANCA-positive. Two clinical subsets exist:• ANCA-positive EGPA → vasculitic manifestations such as glomerulonephritis and neuropathy• ANCA-negative EGPA → eosinophilic disease with pulmonary infiltrates and cardiomyopathyAsthma is a defining feature, and cardiac involvement is a major driver of mortality. Diagnosis relies on modern ANCA testing and organ evaluation. PR3- and MPO-specific immunoassays are now the preferred screening tests, with ~90–95% sensitivity for active GPA/MPA and >95% specificity. Renal disease occurs in 70–80% of GPA/MPA, typically as pauci-immune necrotizing crescentic glomerulonephritis, while pulmonary disease ranges from nodules and cavitation (PR3) to interstitial lung disease (MPO) and diffuse alveolar hemorrhage. Management has evolved dramatically. First-line induction therapy combines glucocorticoids with rituximab or cyclophosphamide, with rituximab preferred for most patients—especially PR3-ANCA or relapsing disease. Reduced-dose steroid regimens are now recommended after trials like PEXIVAS, which showed lower infection risk without worse renal outcomes. We also cover key modern therapies.• Avacopan, a C5a receptor antagonist, improves sustained remission and kidney recovery while reducing steroid exposure.• Plasma exchange remains controversial after the PEXIVAS trial, but may still be considered in severe kidney failure, dialysis-dependent disease, or diffuse alveolar hemorrhage. For maintenance therapy, rituximab is now the preferred agent, outperforming azathioprine in major trials such as MAINRITSAN and RITAZAREM. Maintenance typically continues 2–4 years, especially in PR3-ANCA patients with high relapse risk. We finish with EGPA-specific treatment advances. IL-5 pathway inhibitors have transformed care, including mepolizumab and the newer benralizumab, which improve remission rates and allow significant glucocorticoid reduction. The bottom line: AAV management has shifted toward precision medicine—ANCA serotype classification, complement-targeted therapy, steroid-sparing strategies, and biologic maintenance treatments—dramatically improving survival and long-term outcomes.

In this episode of Hospital Medicine Unplugged, we sprint through thalassemia—an inherited hemoglobinopathy defined by reduced or absent globin chain production, ineffective erythropoiesis, and chronic anemia. We break down the genetics, pathophysiology, clinical spectrum, and why this disorder remains the most common monogenic disease worldwide. We start with the big picture. About 5% of the global population carries an α-thalassemia allele and 1.5% carries a β-thalassemia allele, with roughly 1.3 million people living with disease and ~40,000 affected infants born annually. The condition clusters across malaria-endemic regions—from sub-Saharan Africa and the Mediterranean to the Middle East, South Asia, and Southeast Asia—because the carrier state provides partial protection against malaria. Migration has increasingly brought thalassemia to North America and Europe, expanding its global clinical impact. Next, we revisit normal hemoglobin physiology. Adult hemoglobin (HbA) is α₂β₂, with smaller fractions of HbA₂ (α₂δ₂) and HbF (α₂γ₂). During infancy, the body transitions from fetal hemoglobin to adult hemoglobin as γ-globin declines and β-globin production increases, regulated by transcription factors such as BCL11A and KLF1. Balanced α- and β-chain production is essential—when the balance breaks, unpaired globin chains accumulate, precipitate, and damage developing red cells, driving ineffective erythropoiesis. We then dive into the genetic architecture.α-globin genes (HBA1, HBA2) sit on chromosome 16 with four total copies, while the β-globin gene (HBB) lies on chromosome 11 with two total copies. • α-thalassemia is usually caused by gene deletions affecting HBA1 or HBA2.• β-thalassemia typically results from point mutations affecting transcription, RNA splicing, or translation. Mutations are classified as:• β⁰ mutations: no β-globin production• β⁺ mutations: reduced β-globin synthesis Severity depends on genotype, but genetic modifiers matter—coinherited α-thalassemia, increased HbF production, or α-globin gene duplications can significantly alter disease expression. Next, we map the clinical classification. Alpha thalassemia spectrum:• Silent carrier: one gene affected, usually asymptomatic• α-thalassemia trait: two genes affected, mild microcytic anemia• Hemoglobin H disease: three genes affected → moderate-severe hemolytic anemia with β₄ tetramers• Hb Bart’s hydrops fetalis: four genes deleted → incompatible with life Beta thalassemia spectrum:• β-thalassemia trait: mild microcytic anemia with elevated HbA₂ (>3.5%)• β-thalassemia intermedia: moderate anemia with variable transfusion needs• β-thalassemia major (Cooley anemia): severe disease presenting in infancy requiring lifelong transfusions Compound disorders add complexity, including HbE-β thalassemia and sickle-β thalassemia, where severity depends on the interacting mutations. Then we unpack the pathophysiology driving complications. Excess unpaired globin chains cause oxidative damage and premature death of erythroid precursors, leading to:• Ineffective erythropoiesis with massive marrow expansion• Hemolysis from fragile red cells• Extramedullary hematopoiesis in liver and spleen Chronic erythropoietin stimulation leads to skeletal deformities—frontal bossing, maxillary hypertrophy, and long-bone abnormalities. Iron overload develops through two major pathways:• Transfusion iron loading (each unit adds ~200–250 mg of iron)• Increased intestinal absorption from suppressed hepcidin due to ineffective erythropoiesis The downstream damage is systemic: cardiomyopathy, arrhythmias, liver fibrosis and cirrhosis, endocrine failure (growth delay, diabetes, hypothyroidism, hypoparathyroidism), osteoporosis, and thrombosis risk. We close with the clinical spectrum. • Trait: usually asymptomatic with incidental microcytosis• Intermedia: moderate anemia (Hb ~7–10 g/dL), skeletal changes, gallstones, pulmonary hypertension, extramedullary masses• Major: early in

In this episode of Hospital Medicine Unplugged, we sprint through prosthetic heart valves—how to choose between mechanical and bioprosthetic valves, manage anticoagulation safely, recognize complications, and navigate the expanding role of transcatheter valve replacement. We begin with the two major categories of prosthetic valves: mechanical valves and bioprosthetic (tissue) valves. Mechanical valves are constructed from durable materials such as pyrolytic carbon and are designed to last decades, but their thrombogenic surface requires lifelong anticoagulation with a vitamin K antagonist. Anticoagulation targets depend on valve position and risk factors.• Mechanical aortic valve: target INR 2.5• Mechanical mitral valve or high-risk aortic valve: target INR 3.0 In most patients, low-dose aspirin (75–100 mg daily) is added to vitamin K antagonist therapy to further reduce thromboembolic risk. Bioprosthetic valves, in contrast, are made from porcine valves or bovine pericardium. These valves are less thrombogenic, which allows for short-term anticoagulation (typically 3–6 months) after implantation followed by lifelong antiplatelet therapy with aspirin. The trade-off is durability—structural valve degeneration (SVD) eventually occurs due to calcification, fibrosis, or leaflet tearing. Choosing between valve types requires balancing durability versus anticoagulation risk. Mechanical valves generally offer better long-term durability, while bioprosthetic valves avoid lifelong anticoagulation but may require future reoperation. Age is one of the most important factors in valve selection. Evidence from large observational studies demonstrates that mechanical valves provide survival advantages in younger patients, particularly:• Aortic valve replacement: survival benefit up to about age 55• Mitral valve replacement: survival benefit up to about age 70 Current ACC/AHA guidelines generally recommend:• Mechanical valves: younger patients (<50 years for aortic position, <65 years for mitral)• Bioprosthetic valves: older patients or those with contraindications to long-term anticoagulation The treatment landscape has changed dramatically with the development of transcatheter aortic valve replacement (TAVR). Initially reserved for patients with prohibitive surgical risk, TAVR is now widely used across risk groups. Landmark trials such as PARTNER 3 demonstrated that in low-risk patients with severe aortic stenosis, TAVR produced outcomes comparable to surgical valve replacement at five years. TAVR offers advantages including lower rates of atrial fibrillation and bleeding, though it carries higher risks of paravalvular regurgitation and pacemaker implantation. Guidelines now recommend:• TAVR as a Class I option for patients who are inoperable or high surgical risk• Either TAVR or surgical replacement for patients aged 65–80 years, depending on anatomy and patient factors Anticoagulation management remains one of the most critical aspects of prosthetic valve care. Direct oral anticoagulants (DOACs are contraindicated in mechanical valves). The RE-ALIGN trial showed increased thromboembolic and bleeding complications with dabigatran compared with warfarin, leading to early termination of the study. More recently, the PROACT Xa trial evaluating apixaban in patients with On-X mechanical valves also demonstrated excess thromboembolic events. For bioprosthetic valves, however, DOACs may be used in patients who develop atrial fibrillation, although long-term data remain limited. Despite technological advances, prosthetic valves carry important complications. One of the most serious is prosthetic valve endocarditis (PVE), which is associated with high mortality. Management requires prolonged intravenous antibiotics, typically for at least six weeks, and surgery may be required for heart failure, uncontrolled infection, or large vegetations. Another major complication is prosthetic valve thrombosis, particularly with mechanical val

In this episode of Hospital Medicine Unplugged, we sprint through glomerulonephritis—recognize the nephritic syndrome, decode complement patterns and immunofluorescence clues, and manage diseases ranging from self-limited post-infectious GN to rapidly progressive crescentic disease. We start with the clinical syndrome of glomerulonephritis, defined by glomerular inflammation producing hematuria, hypertension, edema, and reduced kidney function. The classic picture is nephritic syndrome—tea- or cola-colored urine, oliguria, periorbital edema, and elevated blood pressure. At the microscopic level, RBC casts are the pathognomonic finding, proving that bleeding originates from the glomerulus rather than the urinary tract. Understanding disease requires revisiting the glomerular filtration barrier, composed of three layers: fenestrated endothelium, the glomerular basement membrane (GBM), and podocytes connected by slit diaphragms. This barrier normally filters plasma while retaining proteins. Podocytes are terminally differentiated and poorly regenerative, making them particularly vulnerable to immune-mediated injury. The core pathophysiology of GN is immune-mediated inflammation. Antibodies, immune complexes, and complement activation trigger inflammatory cascades within the glomerulus. This leads to endocapillary proliferation, mesangial expansion, and leukocyte infiltration, narrowing capillary lumens and lowering GFR. Capillary wall damage allows red blood cells to leak into urine, while the sudden decline in filtration drives sodium and water retention, producing hypertension and edema. Modern classification emphasizes pathogenesis rather than morphology, and most GN falls into five categories: • Immune-complex GN – granular immunoglobulin deposition (post-infectious GN, IgA nephropathy, lupus nephritis, MPGN)• Pauci-immune GN – minimal immune deposition, typically ANCA-associated vasculitis• Anti-GBM disease – linear IgG staining along the basement membrane• Monoclonal immunoglobulin GN – related to plasma cell disorders• C3 glomerulopathy – dominant complement deposition from alternative pathway dysregulation Epidemiology varies by disease. Post-streptococcal GN primarily affects children aged 2–10 years, particularly in developing regions. In contrast, IgA nephropathy is the most common primary glomerular disease worldwide and typically presents in young adults. Interestingly, epidemiology has shifted: childhood PSGN is declining, while adult infection-related GN—often associated with staphylococcal infections—is increasing. Clinical presentation depends on the underlying disease. Post-streptococcal GN typically occurs 1–12 weeks after a streptococcal infection, producing abrupt edema, hypertension, and hematuria. IgA nephropathy, in contrast, often presents with synpharyngitic hematuria—visible hematuria occurring simultaneously with an upper respiratory infection. The urinalysis is the diagnostic cornerstone. Key findings include dysmorphic red blood cells, RBC casts, and mild-to-moderate proteinuria. Complement levels help narrow the differential: • Low C3 and low C4: lupus nephritis, cryoglobulinemia, immune-complex MPGN• Low C3 with normal C4: post-infectious GN or C3 glomerulopathy• Normal complement: IgA nephropathy, ANCA-associated GN, anti-GBM disease A crucial teaching point: C3 should normalize within 6–8 weeks in post-streptococcal GN. Persistent hypocomplementemia suggests another diagnosis, such as lupus nephritis or MPGN. Additional testing includes ASO titers and anti-DNase B antibodies for streptococcal infection, autoimmune markers such as ANA and ANCA, and viral testing for hepatitis B, hepatitis C, and HIV. Imaging plays a limited role. Renal ultrasound typically shows normal or enlarged kidneys in acute GN, helping distinguish acute inflammatory disease from chronic kidney disease. When the diagnosis remains unclear—or when disease is severe—a kidney biopsy is essential. Histology reveals ch

In this episode of Hospital Medicine Unplugged, we sprint through anaphylaxis—recognize the rapid systemic reaction, understand the mast-cell storm driving shock, and deliver epinephrine immediately to prevent cardiovascular collapse. We begin with the definition and diagnostic framework. Anaphylaxis is a severe, rapid-onset, life-threatening systemic hypersensitivity reaction. When it progresses to circulatory collapse with profound vasodilation and vascular leak, it becomes anaphylactic shock, a form of distributive shock with relative hypovolemia. Modern guidelines define anaphylaxis clinically: acute onset of illness with skin or mucosal symptoms plus respiratory compromise, hypotension, or severe gastrointestinal symptoms, or hypotension/bronchospasm after known allergen exposure—even without skin findings. Next comes epidemiology. Anaphylaxis occurs in roughly 50–112 episodes per 100,000 person-years, and 1.6–5.1% of adults in the United States experience an episode during their lifetime. Fortunately, modern treatment has kept mortality low. Case fatality rates among emergency presentations are about 0.25–0.33%, translating to roughly 186–225 deaths per year in the United States. Triggers vary by age. Food-induced anaphylaxis predominates in young children, while medication-induced reactions are more common in adults, especially those over age 50. At the core of anaphylaxis lies mast-cell and basophil activation. In classic IgE-mediated type I hypersensitivity, an allergen first sensitizes the immune system, leading B cells to produce IgE antibodies that bind to high-affinity FcεRI receptors on mast cells and basophils. On re-exposure, allergen cross-linking of IgE triggers rapid cellular degranulation. This releases a cascade of mediators including: • Histamine and tryptase• Leukotrienes and prostaglandins• Platelet-activating factor (PAF)• Cytokines such as IL-4 and IL-6 These mediators cause vasodilation, endothelial barrier disruption, bronchoconstriction, and massive capillary leak, shifting fluid from the intravascular space to tissues. The result is hypotension, airway compromise, and multisystem dysfunction. Not all anaphylaxis is IgE mediated. Alternative mechanisms include IgG-mediated reactions, complement activation, contact system activation, and direct mast-cell activation via MRGPRX2 receptors. Clinically, these non-IgE pathways can produce identical presentations, which is why anaphylaxis remains a clinical diagnosis rather than a laboratory one. The most common triggers fall into three major groups: • Foods (≈32–37%)• Medications (≈21–58%)• Insect venom (≈15–25%) In the United States, nine foods account for over 90% of IgE-mediated food allergies: milk, egg, wheat, soy, peanuts, tree nuts, fish, shellfish, and sesame. Peanuts remain the leading cause of fatal food-related anaphylaxis. An emerging cause is alpha-gal syndrome, a delayed meat allergy triggered by tick bites, affecting tens to hundreds of thousands of individuals in the United States. Medications are the most common trigger in adults, particularly beta-lactam antibiotics, followed by NSAIDs, biologic agents, chemotherapy drugs, and ACE inhibitors. Another important concept is cofactors—conditions that lower the threshold for anaphylaxis. These include exercise, alcohol, infection, menstruation, and NSAID use. A classic example is food-dependent exercise-induced anaphylaxis, where patients tolerate a food normally but develop anaphylaxis if they exercise soon after ingestion. Diagnosis relies on clinical criteria, most commonly the NIAID/FAAN criteria. Anaphylaxis is highly likely when there is acute involvement of skin or mucosa plus respiratory compromise or hypotension, multisystem involvement after allergen exposure, or isolated hypotension after exposure to a known trigger. Laboratory confirmation is not required in the acute setting, but serum tryptase measured 90 minutes to 4 hours after symptom onset can support the diagno

In this episode of Hospital Medicine Unplugged, we break down endovascular infections—vascular graft infections, mycotic aneurysms, CIED infections, and septic thrombophlebitis syndromes—focusing on modern epidemiology, evolving microbiology, advanced imaging, and high-yield management strategies. We begin with epidemiology clinicians should know. Vascular graft infections occur in ~0.5–6% of vascular reconstructions, while endovascular device infections occur in ~0.2–5% of procedures, with TEVAR carrying higher infection risk than abdominal repairs. Meanwhile, cardiac implantable electronic device (CIED) infections have increased substantially, reflecting growing device use. Next we review key microbiology. Gram-positive cocci cause most vascular graft infections, with coagulase-negative staphylococci now more common than S. aureus. MRSA is increasingly prevalent and linked to worse outcomes, while Pseudomonas aeruginosa leads among gram-negative pathogens. For mycotic aneurysms, Salmonella species remain classic causes, with rare pathogens including Listeria and Mycobacterium tuberculosis. We then highlight important clinical syndromes.Lemierre syndrome presents with pharyngitis, internal jugular vein thrombosis, and septic emboli (often pulmonary) and is classically caused by Fusobacterium necrophorum, though MRSA and polymicrobial infections are increasingly recognized. Pylephlebitis, sometimes called the abdominal variant of Lemierre syndrome, involves septic thrombosis of the portal venous system. Diagnosis relies heavily on advanced imaging. CTA is typically the first-line test, while 18F-FDG PET/CT provides high sensitivity (~94%) and excellent negative predictive value, especially in late graft infections. TEE remains essential for suspected CIED infection, though repeat imaging may be needed if initial studies are negative. Management requires combined antimicrobial and procedural strategies.• ≥6 weeks of antibiotics for most vascular graft infections• Device removal for confirmed CIED infection, with early extraction improving survival• 3–6 weeks of antibiotics for Lemierre syndrome, often metronidazole plus a β-lactam, with MRSA coverage in high-risk patients• Lifelong suppressive therapy may be needed when infected devices cannot be removed We close with key controversies and outcomes. Anticoagulation for septic thrombophlebitis remains debated, though many experts consider 6–12 weeks of therapy in selected patients. Despite advances, vascular graft infections and mycotic aneurysms carry high mortality—often exceeding 30% at one year—especially with MRSA. Early recognition, PET/CT-guided diagnosis, aggressive antibiotics, and timely device removal remain the pillars of care for these complex infections.

In this episode of Hospital Medicine Unplugged, we sprint through urticaria—recognize the wheal, distinguish acute from chronic disease, uncover autoimmune drivers, and step through a modern treatment ladder that now includes biologics and BTK inhibitors. We start with the definition and epidemiology. Urticaria is characterized by transient pruritic wheals, angioedema, or both, typically resolving within 24 hours without scarring. While about 20% of people experience urticaria at some point in life, chronic spontaneous urticaria (CSU) affects roughly 1% of the population and disproportionately affects women aged 30–50. The key classification hinges on duration.• Acute urticaria: symptoms lasting <6 weeks• Chronic urticaria: symptoms ≥6 weeks Fortunately, progression from acute to chronic disease occurs in fewer than 8% of cases. Risk factors for chronicity include antithyroid antibodies and poor response to antihistamines. Next comes an important shift in our understanding of etiology. Historically, chronic urticaria was labeled “idiopathic” in most cases. We now know that more than half of patients actually have autoimmune disease mechanisms. Two major autoimmune endotypes exist: Type I autoimmune (autoallergic) CSU• IgE autoantibodies against autoantigens such as thyroid peroxidase or IL-24• Leads to mast-cell activation similar to allergic disease Type IIb autoimmune CSU• IgG autoantibodies against IgE or the FcεRI receptor• Identified in about 8–10% of patients using strict diagnostic criteria These immune mechanisms explain why less than 35% of CSU cases truly lack detectable autoantibodies. Diagnosis is largely clinical but follows the “7C” framework:Confirm diagnosis, identify causes, assess cofactors, evaluate comorbidities, assess consequences, evaluate biomarkers, and monitor disease course. Routine laboratory testing should remain minimal unless clinical clues suggest otherwise. Recommended baseline tests include:• CBC with differential• ESR or CRP• TSH Certain red flags should trigger referral or further evaluation:• Wheals lasting >24 hours• Residual hyperpigmentation after lesions resolve• Angioedema lasting several days without hives• Systemic symptoms such as fever, arthralgia, or abdominal pain To measure disease activity, clinicians rely on validated tools. The Urticaria Activity Score over 7 days (UAS7) is the gold standard. Patients record itch severity and hive count twice daily, producing a score from 0 to 42. Interpretation:• 0: urticaria-free• 1–6: well controlled• 7–15: mild• 16–27: moderate• 28–42: severe The Urticaria Control Test (UCT) is another practical tool. A score ≥12 indicates good control, while <12 suggests poorly controlled disease. Management follows a stepwise escalation strategy. Step 1: Second-generation H1 antihistaminesAgents include cetirizine, loratadine, fexofenadine, levocetirizine, and desloratadine, taken daily rather than as needed. About 40% of patients achieve meaningful symptom reduction with standard dosing. Step 2: Dose escalationIf symptoms persist, antihistamine doses can be increased up to fourfold. Evidence suggests quadrupling the dose of a single antihistamine is more effective than combining multiple agents. Step 3: OmalizumabFor antihistamine-refractory disease, omalizumab 300 mg every 4 weeks is the standard biologic therapy. Clinical trials show complete remission (UAS7 = 0) in about 36% of patients, with substantially higher response rates in real-world practice. Patients with incomplete response may require higher doses or shorter dosing intervals. Step 4: CyclosporineFor patients who fail omalizumab, cyclosporine (3–5 mg/kg/day) can improve symptoms in more than half of cases, although monitoring for renal toxicity and hypertension is essential. Short courses of systemic corticosteroids (20–50 mg/day for <10 days) may help during severe flares but should never be used long-term. The treatment landscape is expanding rapidly. Two newly a

In this episode of Hospital Medicine Unplugged, we sprint through status epilepticus—stop the seizure fast, escalate therapy on time, protect the brain, and treat the cause before refractory disease sets in. We begin with the modern definition that changed emergency care. Status epilepticus is now defined as ≥5 minutes of continuous seizure activity or ≥2 seizures without return to baseline. The old 30-minute threshold is obsolete because neuronal injury and benzodiazepine resistance begin early, driven by GABA receptor internalization within minutes of sustained seizure activity. That’s why treatment must begin within the first 5–10 minutes. The stakes are high: incidence is 10–40 per 100,000 annually, with 10–20% adult mortality, rising sharply in refractory cases, elderly patients, and acute symptomatic etiologies such as stroke or hypoxic injury. Next comes the first-line intervention—benzodiazepines within 5–10 minutes. These remain Level A evidence therapy and terminate seizures in roughly 65–70% of cases when given promptly and at adequate doses. Three effective options:• IV lorazepam 0.1 mg/kg (max 4 mg), may repeat once• IM midazolam 10 mg (0.3 mg/kg in children) — preferred if IV access unavailable• IV diazepam 0.15 mg/kg, may repeat once The biggest real-world mistake isn’t drug choice—it’s delay and underdosing. If seizures persist, move quickly to second-line “urgent control” therapy (10–20 minutes). The landmark ESETT trial compared levetiracetam, fosphenytoin, and valproate in benzodiazepine-refractory status epilepticus and fundamentally changed practice. The key finding: all three drugs work equally well, stopping seizures in about 47–52% of patients. Recommended doses:• Levetiracetam 60 mg/kg (max 4500 mg)• Fosphenytoin 20 mg PE/kg• Valproate 40 mg/kg Because efficacy is equivalent, patient factors guide the choice:• Cardiac disease → avoid fosphenytoin (hypotension/arrhythmia risk)• Pregnancy or liver disease → avoid valproate• Simplest safety profile → levetiracetam Other alternatives include lacosamide or phenobarbital, though ESETT drugs remain the most widely used. When seizures continue despite these steps, the patient has entered refractory status epilepticus, which occurs in 23–43% of cases. At this stage, escalation means ICU care, intubation, and continuous EEG monitoring. Third-line therapy involves continuous anesthetic infusions designed to suppress cortical activity: • Propofol (20–200 mcg/kg/min) — rapid onset but risk of propofol infusion syndrome with prolonged use• Midazolam infusion — commonly used but tachyphylaxis develops• Pentobarbital coma — powerful seizure suppression but high rates of hypotension and prolonged sedation Most modern practice favors propofol or midazolam over barbiturate coma. A newer strategy gaining traction is ketamine, an NMDA receptor antagonist with a completely different mechanism from GABAergic drugs. Unlike other anesthetics, ketamine preserves blood pressure and respiratory drive, making it a useful adjunct in refractory disease. If seizures continue ≥24 hours despite anesthetic therapy, the condition becomes super-refractory status epilepticus, a devastating scenario with mortality approaching 40–50%. Management expands to include:• Ketamine infusions• Immunotherapy (steroids, IVIG, plasmapheresis) when autoimmune etiologies are suspected• Ketogenic diet• Neuromodulation or epilepsy surgery in select cases Two particularly challenging syndromes fall into this category:NORSE (New Onset Refractory Status Epilepticus) and FIRES (Febrile Infection-Related Epilepsy Syndrome), often requiring aggressive immunologic treatment. Throughout all stages, clinicians must identify and treat the underlying cause—the strongest determinant of outcome. Prognosis varies dramatically depending on response to therapy:• Benzodiazepine-responsive SE: <5% mortality• Second-line responsive SE: ~10–15% mortality• Refractory SE: 20–40% mortality• Super-refractory SE: up

In this episode of Hospital Medicine Unplugged, we sprint through aplastic anemia—recognize the pancytopenia, confirm marrow failure, suppress the immune attack, and watch for clonal evolution. We open with the diagnostic framework that defines disease severity. The Camitta criteria remain the standard classification. Severe aplastic anemia requires bone marrow cellularity <25% plus at least two of three cytopenias:• ANC <500/μL• Platelets <20,000/μL• Reticulocytes <60,000/μL Very severe disease is defined by ANC <200/μL, a group at extremely high infection risk. These criteria matter because treatment decisions hinge on severity, patient age, and donor availability. Next, we unpack the pathophysiology—the immune system attacking hematopoiesis. In acquired aplastic anemia, cytotoxic T cells target hematopoietic stem and progenitor cells (HSPCs). These T cells release interferon-γ and TNF-α, which activate Fas/Fas-ligand pathways, triggering apoptosis of stem cells and collapsing bone marrow production. Recent discoveries explain how immune escape and clonal selection occur. IFN-γ suppresses HSPCs expressing HLA class I molecules, while HLA-deficient clones evade immune destruction, creating a survival advantage in about 30% of patients. Meanwhile, regulatory T cells are decreased, and their restoration often parallels hematologic recovery. Then comes one of the biggest therapeutic advances in decades: adding eltrombopag to immunosuppressive therapy. Standard treatment has long been horse antithymocyte globulin (ATG) plus cyclosporine, but the RACE trial changed the landscape. When eltrombopag was added:• Complete response at 3 months doubled (22% vs 10%)• Overall response at 6 months increased to 68% vs 41%• Median time to response shortened from 8.8 months to 3 months Because of these results, ASH 2025 guidelines now recommend eltrombopag alongside ATG and cyclosporine for severe and very severe aplastic anemia in both adults and children. Beyond thrombopoiesis, eltrombopag appears to stimulate stem-cell recovery and counteract IFN-γ–mediated suppression. For curative therapy, we turn to hematopoietic stem cell transplantation. Modern guidelines use age-based decision pathways: • <20 years: matched sibling transplant or immunosuppressive therapy• 20–40 years: matched unrelated donor transplant or immunosuppressive therapy• >40 years: immunosuppressive therapy preferred Haploidentical transplant is generally reserved for later lines, with immunosuppressive therapy favored initially. Another hallmark of aplastic anemia is its relationship with paroxysmal nocturnal hemoglobinuria (PNH). Up to 50% of patients harbor a PNH clone, detectable by FLAER-based flow cytometry with CD55/CD59 testing. Importantly, the presence of a PNH clone is actually a favorable prognostic sign. Patients with PNH clones show:• Better response to immunosuppressive therapy (≈78% vs 50%)• Better transplant outcomes (≈97% vs 77%)• Lower risk of progression to myelodysplastic syndrome The mechanism is elegant: GPI-negative stem cells with PIGA mutations escape immune destruction, allowing them to survive when normal HSPCs are targeted. Despite improved survival, long-term complications remain a major concern. About 10–20% of patients develop clonal evolution to myelodysplastic syndrome or acute myeloid leukemia within 10 years, particularly after immunosuppressive therapy. Genomic studies show clonal hematopoiesis in roughly half of patients, with mutation patterns predicting outcomes:• DNMT3A and ASXL1 → higher risk of clonal expansion and progression to MDS/AML• BCOR, BCORL1, and PIGA → better response and more stable disease Risk factors for clonal evolution include older age, poor response to immunosuppressive therapy, high-risk mutations, and multiple mutations with higher allele burden. When secondary myeloid malignancies occur, they often carry high-risk cytogenetics such as monosomy 7 or complex karyotypes, with ~40%

In this episode of Hospital Medicine Unplugged, we tackle one of the most ethically charged and clinically challenging topics in inpatient care: the use of restraints in the hospital setting. When are restraints justified, why do we still use them so often, and what does the evidence actually show about benefit versus harm? We start by defining physical restraints—any device or method that limits a patient’s movement, from wrist and ankle restraints to vests, belts, bed rails, and enclosure beds—and chemical restraints, medications used primarily to control behavior rather than treat an underlying condition. We unpack why experts increasingly reject the term “chemical restraint,” emphasizing pharmacologic treatment of agitation aimed at calming, not sedating, patients while addressing root causes. Next, we explore why restraints are used: fall prevention, prevention of device removal, management of delirium or agitation, and protection of staff. But here’s the paradox—observational data consistently show higher rates of the very outcomes restraints are meant to prevent, including unplanned extubations, device removal, increased agitation, delirium, and longer ICU stays. We break down the scope of the problem. Nearly 1 in 10 hospitalized patients experiences restraint use, with rates approaching 40% of ICU encounters and even higher among mechanically ventilated patients. Use varies widely by setting, staffing, and culture—highlighting that restraint use is often system-driven, not patient-driven. The heart of the episode focuses on ethics and law. Restraints represent a profound restriction of liberty, and ethical use requires three conditions: medical appropriateness, informed consent (or a valid emergency exception), and use of the least restrictive option. We review federal regulatory requirements—restraints only for imminent harm, after less restrictive measures fail, time-limited orders, mandatory face-to-face evaluations, continuous monitoring, and early removal. We then confront the real harms. Physically: DVT, PE, aspiration pneumonia, fractures, pressure injuries, rhabdomyolysis, asphyxiation, and death. Psychologically: fear, loss of dignity, and PTSD, affecting up to 25–47% of patients after a restraint event. These risks rise with each additional day of restraint use. From there, we pivot to what actually works: alternatives. Multicomponent, non-pharmacologic strategies—reorientation, sleep hygiene, pain control, early mobility, family engagement, sitters, sensory optimization, and delirium prevention bundles like ABCDEF—reduce delirium and restraint use by 40–60% while improving outcomes. We close with practical takeaways: assess underlying causes first (pain, hypoxia, infection, withdrawal, delirium), use verbal de-escalation and environment before meds, reserve restraints for true emergencies, document meticulously, reassess relentlessly, and remove early. The bottom line: restraints are not benign, not preventive, and not routine care—they are a last resort in modern, patient-centered hospital medicine. Fast, evidence-driven, and ethically grounded—protect safety without sacrificing dignity.

In this episode of Hospital Medicine Unplugged, we tackle one of the most anxiety-provoking inpatient consults: acute facial weakness—Bell’s palsy or stroke? We break down how to tell them apart fast, why the distinction matters, and how to manage each safely in hospitalized patients. We start with the bedside exam that saves lives. Forehead involvement = peripheral (Bell’s palsy); forehead sparing = central (stroke)—until proven otherwise. Bell’s palsy presents with acute unilateral facial paralysis involving the forehead, often peaking within 72 hours, and may include post-auricular pain, altered taste, hyperacusis, or dry eye, without other neurologic deficits. Stroke typically hits suddenly, often spares the forehead, and comes with red flags like limb weakness, aphasia, gaze deviation, dysphagia, or altered mental status. We walk through the don’t-miss pitfalls: brainstem strokes that mimic a lower motor neuron pattern, bilateral facial weakness, gradual or progressive onset, recurrent ipsilateral palsy, hearing loss or vertigo, and facial palsy in post-op, ICU, immunocompromised, or cancer patients—all of which demand a lower threshold for imaging and expanded workup. Next, the inpatient diagnostic strategy. Suspect stroke? Activate the stroke alert—determine last known well, check glucose, perform a focused neuro exam, and get emergent CT/MRI. For classic Bell’s palsy, routine labs and imaging aren’t required, but in hospitalized patients consider MRI with contrast or CSF if there are atypical features, infection risk, multiple cranial nerves involved, or no improvement by 3–6 weeks. Treatment pearls you can use today:Bell’s palsy—start oral corticosteroids within 72 hours (prednisone 50–60 mg daily x5 days, then taper). This improves complete recovery (NNT ≈10). Antivirals alone don’t work; adding them to steroids may modestly reduce synkinesis, especially in severe paralysis. Eye protection is non-negotiable: artificial tears, nighttime ointment, and a moisture shield—early ophthalmology if exposure risk.Stroke—time is brain. Eligible patients get IV thrombolysis and/or mechanical thrombectomy based on time and imaging, with guideline-directed blood pressure control, antithrombotics, and early rehab. We close with prognosis and counseling. Bell’s palsy has a 70–85% complete recovery rate (higher with early steroids), but 25–40% may have residual weakness or synkinesis—plan follow-up at 3 months if recovery lags. Stroke outcomes hinge on severity and speed to reperfusion, making rapid recognition critical. Bottom line: Examine the forehead, hunt for red flags, image early when in doubt, protect the eye, treat fast, and never miss a stroke.